Table 2.

Post OLT HBV-vaccine administration trials

Methods	No. of patients	Definition of success	Success rate (%)	Reference no.	Year published
Liver cirrhosis
Novel adjuvant MPL/QS2 vaccine for 0, 4, 16, 18 weeks	16	HBsAb >500 IU/L without HBIG	80	48	2007
Experimental adjuvant vaccine for 0, 1, 2, 6, 12 months	8	HBsAb >500 IU/L, 18 months without HBIG	25	49	2005
40 mg for 0, 1, 2, 6, 7, 8 months	18	HBsAb >500 IU/L, 12 weeks after last vaccination	0	50	2009
10–20 mg/month with minimal immune suppression	17	HBsAb >100 IU/L, without HBIG	64	51	2009
20 mg/month of MPL adjuvant for 12 months	18	HBsAb >100 IU/L, 18 months without HBIG	44.4	52	2010
20 mg/month	22	HBsAb >100 IU/L, 6 months without HBIG	40	53	2012
20 mg/month	15	HBsAb >100 IU/L, 3 months without HBIG	0	47	2011
40 mg 0, 1, 2, 3 months, 20 mg 4, 5, 6 months	50	HBsAb >60 IU/L, 3 months without HBIG	24.6	54	2013
40 mg 0, 7, 14, 28 days, 20 mg 2, 3, 4 months	45	HBsAb >60 IU/L, 3 months without HBIG	8.8	54	2013
40 mg 0, 1, 6 months	17	HBsAb >10 IU/L without HBIG	82	55	2000
40 mg for 0, 1, 2, 3, 4, 5 months	52	HBsAb >10 IU/L without HBIG	7.7	56	2005
40 mg for 0, 1, 6 months and additional 0, 1, 2 months if no-response	14	HBsAb >10 IU/L, 3 months without HBIG	7	57	2005
20–40 mg for 0, 1, 6 months	12	HBsAb >10 IU/L, 16 months without HBIG	0	58	2010
40 mg for 0, 1, 2, 6, 7, 8 months	7	HBsAb >10 IU/L without HBIG	0	59	2006
Acute liver failure
20 mg/month	5	HBsAb >100 IU/L, 6 months without HBIG	100	53	2012
10–20 mg/month with minimal immunosuppression	3	HBsAb >100 IU/L without HBIG	66	51	2009
Experimental adjuvant vaccine for 0, 1, 2, 6, 12 months	2	HBsAb >500 IU/L, 18 months without HBIG	100	49	2005

HBIG, hepatitis B immunoglobulin; HBsAb, hepatitis B surface antibody; HBV, hepatitis B virus; OLT, orthotopic liver transplantation.